BeOne Medicines (NASDAQ:ONC) SVP Chan Henry Lee Sells 428 Shares of Stock

BeOne Medicines Ltd. – Sponsored ADR (NASDAQ:ONC) SVP Chan Henry Lee sold 428 shares of the company’s stock in a transaction on Thursday, June 11th. The stock was sold at an average price of $257.63, for a total transaction of $110,265.64. Following the sale, the senior vice president directly owned 346,554 shares in the company, valued at $89,282,707.02. This trade represents a 0.12% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Chan Henry Lee also recently made the following trade(s):

• On Monday, June 8th, Chan Henry Lee sold 871 shares of BeOne Medicines stock. The stock was sold at an average price of $270.42, for a total transaction of $235,535.82.
• On Wednesday, May 13th, Chan Henry Lee sold 332 shares of BeOne Medicines stock. The stock was sold at an average price of $310.72, for a total transaction of $103,159.04.
• On Wednesday, April 8th, Chan Henry Lee sold 332 shares of BeOne Medicines stock. The shares were sold at an average price of $311.59, for a total transaction of $103,447.88.

BeOne Medicines Price Performance

BeOne Medicines stock opened at $268.20 on Tuesday. BeOne Medicines Ltd. – Sponsored ADR has a 12 month low of $239.25 and a 12 month high of $385.22. The stock’s 50 day moving average is $298.56 and its 200-day moving average is $314.03. The company has a current ratio of 3.64, a quick ratio of 3.27 and a debt-to-equity ratio of 0.20. The company has a market capitalization of $29.43 billion, a price-to-earnings ratio of 60.00 and a beta of 0.49.

BeOne Medicines (NASDAQ:ONC) last posted its earnings results on Wednesday, April 1st. The company reported $0.25 EPS for the quarter. BeOne Medicines had a return on equity of 12.06% and a net margin of 8.94%.The company had revenue of $1.51 billion for the quarter. Equities research analysts expect that BeOne Medicines Ltd. – Sponsored ADR will post 6.14 EPS for the current year.

Institutional Investors Weigh In On BeOne Medicines

Hedge funds have recently made changes to their positions in the stock. EFG International AG acquired a new stake in shares of BeOne Medicines in the 4th quarter valued at approximately $25,000. Leonteq Securities AG acquired a new stake in shares of BeOne Medicines in the 4th quarter valued at approximately $35,000. Daiwa Securities Group Inc. acquired a new stake in shares of BeOne Medicines in the 2nd quarter valued at approximately $35,000. CWM LLC boosted its position in BeOne Medicines by 32.8% during the 4th quarter. CWM LLC now owns 158 shares of the company’s stock worth $48,000 after buying an additional 39 shares during the period. Finally, Group One Trading LLC acquired a new stake in BeOne Medicines during the 4th quarter worth approximately $61,000. 48.55% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

ONC has been the topic of several recent analyst reports. Barclays raised their target price on shares of BeOne Medicines from $405.00 to $409.00 and gave the company an “overweight” rating in a report on Thursday, May 7th. Wall Street Zen raised shares of BeOne Medicines from a “buy” rating to a “strong-buy” rating in a report on Saturday, May 9th. Truist Financial reissued a “buy” rating and issued a $413.00 target price (up from $411.00) on shares of BeOne Medicines in a report on Thursday, May 7th. Wells Fargo & Company initiated coverage on shares of BeOne Medicines in a report on Monday, May 4th. They issued an “overweight” rating and a $400.00 target price on the stock. Finally, Zacks Research raised shares of BeOne Medicines from a “hold” rating to a “strong-buy” rating in a report on Thursday, June 4th. Two research analysts have rated the stock with a Strong Buy rating, eleven have given a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $390.00.

About BeOne Medicines

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Basel, Switzerland.